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Summary
In mammals lipoic acid (LA) and its reduced form dihydrolipoic acid (DHLA) function as cofac-
tors for multienzymatic complexes catalyzing the decarboxylation of α-ketoacids. Moreover, 
LA is used as a drug in a variety of diseases including inflammatory diseases. The aim of the 
study was to examine anti-inflammatory properties of LA metabolites. 
The present paper reports the chemical synthesis of 2,4-bismethylthio-butanoic acid (BMTBA) 
and tetranor-dihydrolipoic acid (tetranor-DHLA). BMTBA is one of the biotransformation pro-
ducts of LA, while tetranor-DHLA is an analogue of DHLA. Structural identity of these compo-
unds was confirmed by 1H NMR. These compounds were assessed for their anti-inflammatory 
activity in mice. For this purpose, the zymosan-induced peritonitis and the carrageenan-in-
duced hind paw edema animal models were applied.
The obtained results indicated that the early vascular permeability measured at 30 min of 
zymosan-induced peritonitis was significantly inhibited in groups receiving BMTBA (10, 30, 
50 mg/kg). The early infiltration of neutrophils measured at 4 hours of zymosan-induced pe-
ritonitis was inhibited in the group receiving BMTBA (50 mg/kg) and tetranor-DHLA (50 mg/
kg). The results indicated that the increase in paw edema was significantly inhibited in the 
groups receiving BMTBA (50, 100 mg/kg) and tetranor-DHLA (30, 50 mg/kg). 
In summary, the present studies clearly demonstrated that both BMTBA and tetranor-DHLA 
were able to act as anti-inflammatory agents. This is the first study examining in vivo the 
anti-inflammatory properties of LA metabolites.
lipoic acid • dihydrolipoic acid • tetranor-dihydrolipoic acid • 2,4-(bismethylthio)-butanoic acid  
• carrageenan • zymosan • anti-inflammatory properties • hydrogen sulfide
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IntroductIon
Lipoic acid (LA, 1,2-dithiolane-3-pentanoic acid; C8H14O2S2) 
and its reduced form dihydrolipoic acid (DHLA, 6,8-dimer-
capto-octanoic acid; C8H16O2S2) are present in all prokary-
otic and eukaryotic cells. DHLA is formed by reduction of 
LA. In humans LA is synthesized by the liver and other 
tissues, and functions as a cofactor for pyruvate dehydro-
genase, α-ketoglutarate dehydrogenase and branched-
chain α-ketoacid dehydrogenase. Moreover, LA and DHLA 
have been proposed to act as antioxidants [1,15,18]. LA 
is used as a therapeutic in a variety of diseases including 
diabetic polyneuropathy, heavy metal intoxication and 
liver diseases [2,7,11]. Furthermore, LA was suggested 
to play a role in cardiovascular protection and can also 
act as an anti-inflammatory agent [3,9,17,22,23,29,34,35].
However, in spite of numerous studies confirming the 
beneficial action of LA for therapy of many diseases, the 
mechanism of its action has not been explained in de-
tail, yet. Therefore, it seems interesting to examine phar-
macological properties of LA metabolites. It is generally 
accepted that biotransformation (phase I and II) of xe-
nobiotics, including drugs, may yield metabolites that 
are either pharmacologically inactive or have stronger, 
weaker or different activity than the parent compound.
Literature data have indicated that (1) LA biotransfor-
mation involves mainly β-oxidation of the carboxylic 
acid side chain and S-methylation of the reduced 1,2-di-
thiolane moiety; (2) 4,6-bismethylthio-hexanoic acid is 
the main circulating LA metabolite in humans; (3) while 
6,8-bismethylthio-octanoic acid and 2,4-bismethylthio-
butanoic acid were shown to be minor metabolites of 
LA [21,25].
The present paper reports the chemical synthesis of 
2,4-bismethylthio-butanoic acid (BMTBA), which is one 
of the LA biotransformation products, and tetranor-dihy-
drolipoic acid (tetranor-DHLA), a DHLA analogue. Struc-
tural identity of these compounds was confirmed by 1H 
NMR.
The safety of BMTBA and tetranor-DHLA was evaluated 
by determining their potential toxicity after acute admin-
istration in mice. Furthermore, these compounds were 
assessed for their anti-inflammatory activity in mice. 
For this purpose, the zymosan-induced peritonitis and 
the carrageenan-induced hind paw edema animal mod-
els were applied.
The obtained results clearly demonstrated that both BM-
TBA and tetranor-DHLA were able to act as anti-inflam-
matory agents. This is the first study examining in vivo 
the anti-inflammatory properties of LA metabolites. 
MaterIals and Methods
Chemical syntheses 
The majority of chemicals were purchased from Sigma-
Aldrich and Fluka. IR spectra were recorded on a Unicam 
Mattson 3020 spectrophotometer as potassium bromide 
discs. The 1H NMR spectra were measured on a Varian 
Mercury VX 300 MHz spectrometer using TMS as the in-
ternal standard. Coupling constant (J) values are estimat-
ed in Hertz (Hz) and spin multiples are given as s (singlet), 
d (double), t (triplet), m (multiplet) and br (broad). Mass 
spectra were measured on a Finnigan MAT 900. Reaction 
courses were monitored by TLC on silica gel precoated 
F254 Merck plates. Developed plates were examined with 
UV lamps (254 nm).
General procedure for preparation of 
2,4-dibromobutanoic acid (2)
To 100 g of γ-butyrolactone, 2 ml of phosphorus tribro-
mide were added and the reaction mixture was heated 
to 100°C. The mixture was stirred while 164 g of bromine 
were added dropwise for 3 hours beneath the surface of 
the liquid (temp. 110-115°C). When the rate of bromine 
uptake decreased, 0.5 ml of phosphorus tribromide was 
added and heat was applied to maintain the reaction tem-
perature. The addition of bromine was continued until 
hydrogen bromide evolution was evident. At that stage 
the product was stirred and cooled to room temperature.
General procedure for preparation of methyl 
2,4-dibromobutanoate (3)
To 68 g of 2,4-dibromobutanoic acid, 120 ml of metha-
nol was added and the resulting solution was saturated 
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with concentrated sulfuric acid. The reaction mixture 
was allowed to stand at room temperature overnight and 
methanol was evaporated under vacuum. The residue was 
extracted with ether. The ether extract was washed with 
3% sodium bicarbonate solution to remove unchanged 
acid and then dried over anhydrous sodium sulfate. The 
solvent was removed and the residue was distilled under 
reduced pressure.
General procedure for preparation of 2,4-bis-
(methylthio)-butanoic acid (4)
100 g of methyl mercaptan were added to a cold solution 
of 78 g of sodium methoxide in 750 ml of methanol. In 
the course of 15 minutes, 105 g of 2,4-dibromobutanoic 
acid were added to the cold stirred mercaptide solution. 
After that the mixture was refluxed for one hour and con-
centrated under vacuum in a water bath. The residue was 
diluted with 500 ml of water and acidified to pH 3 with 6 
M HCl. The acidic fraction was separated by bicarbonate 
extraction followed by acidification and chloroform ex-
traction. The chloroform solution of the acidic product 
was dried over anhydrous magnesium sulfate, filtered 
and concentrated in a vacuum evaporator.
General procedure for preparation of 
2,4-dimercaptobutanoic acid (5)
Thioacetic acid (14.7 g) was cooled in an ice-bath and neu-
tralized with a 10% solution (w/v) of potassium hydrox-
ide in ethanol (approx. 135 ml). To this solution methyl 
2,4-dibromobutanoate (29 g) was added and the mixture 
was stirred and heated under reflux in an atmosphere of 
nitrogen for 5 hours. After cooling of the mixture, 35 g of 
potassium hydroxide were added. Stirring was continued 
until the potassium hydroxide had dissolved and the mix-
ture was then allowed to stand at room temperature in 
an atmosphere of nitrogen overnight. The reaction mix-
ture was acidified (pH<1) with 6 M HCl and concentrated 
under vacuum until an oily layer appeared. Water was 
added to dissolve the inorganic solids. The mixture was 
extracted twice with chloroform, dried over anhydrous 
magnesium sulfate, filtered and concentrated under a 
vacuum evaporator.
2,4-dibromobutanoic acid (2)
Yield 63%; EI-MS m/z 246 (M+).
Methyl 2,4-dibromobutanoate (3)
Yield 86%; EI-MS m/z 274 (M+); 1H NMR (CDCl3, 300 MHz, 
ppm): 2.4-2.6 (m, 2H), 3.54 (t, 2H, J = 6.0 Hz), 3.8 (s, 3H), 
4.52 (t, 1H, J = 7.0 Hz). 
2,4-bis-(methylthio)-butanoic acid (4)
Yield 43%; IR (KBr) cm-1: 1702 (C=O), 678 (C-S); EI-MS m/z 
180 (M+); 1H NMR (CDCl3, 300 MHz, ppm):1.95 (dt, 2H, J = 
7.2 Hz; J = 6.9 Hz), 2.11 (s, 3H), 2.20 (s, 3H), 2.62 (t, 2H, J = 
7.2 Hz), 3.49 (t, 1H, J = 6.9 Hz).
2,4-dimercaptobutanoic acid (5)
Yield 93%; IR (KBr) cm-1: 2560 (S-H), 1703(C=O), 670 (C-S); 
EI-MS m/z 152 (M+); 1H NMR (CDCl3, 300 MHz, ppm): 2.175 
(dt, 2H, J = 6.9 Hz; J = 7.2 Hz), 3.35 (t, 2H, J = 6.9 Hz), 4.4 (t, 
1H, J = 7.2 Hz), 6 (br, 2H).
PharMacoloGIcal Part 
Animals
The experiments were carried out on male Albino-Swiss 
mice (body weight 20-26 g). The animals were housed 
in constant temperature facilities exposed to a 12:12 h 
light-dark cycle, and were maintained on a standard pel-
let diet with tap water available ad libitum. Control and 
experimental groups consisted of eight animals each. All 
experiments were conducted according to guidelines of 
the Animal Use and Care Committee of the Jagiellonian 
University (no. 50/2011 and no. 96/2011, Kraków, Poland).
Acute toxicity
The compounds were suspended in 1% Tween 80 and 
pitched in an ultrasonic cleaner. Acute toxicity was as-
sessed by the methods of Litchfield and Wilcoxon [13] and 
presented as LD50 calculated from mortality of mice after 
24 h. The animals were divided randomly into six groups 
of six animals each. The groups studied were as follows:
group I – tetranor-DHLA (200 mg/kg bw; ip)
group II – tetranor-DHLA (100 mg/kg bw; ip)
group III – tetranor-DHLA (75 mg/kg bw; ip)
group IV – BMTBA (200 mg/kg bw; ip)
group V – BMTBA (400 mg/kg bw; ip)
group VI – BMTBA (1000 mg/kg bw; ip).
Zymosan-induced peritonitis
Peritoneal inflammation was induced as described pre-
viously [10]. Zymosan A was freshly prepared (2 mg/ml) 
in sterile 0.9% NaCl. Thirty min after subcutaneous (sc) 
injection of the investigated compounds into the loose 
skin over the flank, zymosan A was injected ip. Four hours 
later the animals were killed. The peritoneal cavity was la-
vaged with 1.5 ml of saline and after 30 s of gentle manual 
massage the exudates were retrieved. Cells were counted 
Fig.1.  Synthesis of lipoic acid derivatives; (1) γ-butyrolactone; (2) 
2,4-dibromobutanoic acid [BMTBA]; (3) methyl 2,2-dibromobutanoate; (4) 
2,4-bismethylthio-butanoic acid [BMTBA]; (5) 2,4-dimercaptobutanoic acid 
(tetranor-dihydrolipoic acid, tetranor-DHLA)  
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using an automatic cell counter (Countess, Invitrogen) 
following staining with Turk’s solution. The investigated 
compounds were suspended in 1% Tween 80 and pitched 
in an ultrasonic cleaner. The control group was given sc 
1% Tween 80 30 minutes prior to zymosan.
Vascular permeability
Evans blue was suspended in saline (10 mg/ml) and in-
jected intravenously (iv) into the caudal vein, which 
was immediately followed by ip injection of zymosan A. 
Thirty minutes later the animals were killed and their 
peritoneal cavities were lavaged with 1.5 ml of saline 
as described above. The lavage fluid was centrifuged 
and the absorbance of the supernatant was measured 
at 620 nm as described previously [10]. The investigated 
compounds suspended in 1% Tween 80 were injected 
sc 30 min before Evans blue and zymosan. The control 
group was given sc 1% Tween 80 30 min prior to zymo-
san. Indomethacin in a dose of 10 mg/kg bw. was used 
as a reference compound.
Carrageenan-induced paw edema in mice
The test was conducted in 6-week-old mice accord-
ing to the method of Winter with the modification of 
Yazawa [28,31]. The volume of the right hind paw of 
animals was measured. Thirty minutes after the in-
jection ip of the investigated compounds suspended 
in 1% Tween 80, mice were treated with 0.05 ml of 1% 
carrageenan by sc injection into the right hind paw to 
induce acute inflammation. The control group received 
the vehicle (1% Tween 80). Indomethacin in a dose of 
20 mg/kg bw was used as a reference compound. At 1, 
2, 3 h after carrageenan treatment, the degree of paw 
edema was evaluated by measuring the volume of the 
paw using an aqueous plethysmometer (Plethysmom-
eter 7140, Ugo Basile).
The mean values were calculated and the percentage 
change from baseline was determined according to the 
formula:
K  –  the percentage change, 
V0 –  initial paw volume, 
Vt –  volume at time t, 
t  –  time after the measurements.
Statistical analysis
All statistical calculations were carried out with the 
GraphPad Prism 5 program. The statistical signifi-
cance was calculated using Student’s t-test. Differ-
ences were considered statistically significant at p ≤ 
0.05. The LD50 values and their confidence limits were 
calculated according to the method of Litchfield and 
Wilcoxon [13].
K =
Vt − V0
V0
x100
results 
Synthesis of natural LA metabolites
The 2,4-bismethylthio-butanoic acid (BMTBA), which is 
one of the LA biotransformation products, and tetranor-
dihydrolipoic acid (tetranor-DHLA), which is a DHLA 
analogue, were synthesized with good yields by using 
the methods reported for LA preparation with our mod-
ifications (Fig. 1). γ-Butyrolactone (1) was converted to 
2,4-dibromobutanoic acid (2) [19]. 2,4-Di-(methylthio)-
butanoic acid (4) was prepared by adding 2,4-dibromobu-
tanoic acid (2) to an excess of sodium methyl mercaptide 
in methanolic solution and purified by distillation [14]. 
The carboxylic group of 2,4-dimercaptobutanoic acid (2) 
was protected by esterification to methyl ester (3). Treat-
ment of the dibromo ester with potassium thiolacetate 
in ethanol, after alkaline hydrolysis, gave 2,4-dimercap-
tobutanoic acid (5) [20].
Acute toxicity
The LD50 values of the investigated compounds deter-
mined in mice after intraperitoneal (ip) administration 
are shown in Table 1. Tetranor-DHLA was proven to be the 
most toxic compound (LD50 = 75.4 mg/kg). The toxicity of 
BMTBA was over 400 mg/kg. Toxic doses of all the tested 
compounds caused sedation but later increased activity 
and elicited tonic seizures in mice.
Zymosan-induced peritonitis in mice 
The effect of tetranor-DHLA and BMTBA on vascular per-
meability was tested at three doses of the former (10, 
30, 50 mg/kg bw) and four doses of the latter (10, 30, 50 
and 100 mg/kg bw). Indomethacin at a dose of 10 mg/
kg bw was used as a reference compound (IND10 group). 
The early vascular permeability measured at 30 min of 
zymosan-induced peritonitis was significantly inhibited 
in groups receiving BMTBA (BMTBA10, BMTBA30, BMT-
BA50 groups) compared to the control group, which was 
given zymosan alone (Fig. 2, Table 2). On the other hand, 
BMTBA at a dose of 100 mg/kg bw and tetranor-DHLA in 
any of the administered doses did not reduce vascular 
permeability (Fig. 2, Table 2).
The effect of the compounds under study on infiltration 
of neutrophils was tested at one dose of BMTBA (50 mg/
kg bw) or tetranor-DHLA (50 mg/kg bw). The early in-
filtration of neutrophils measured at 4 hours of zymo-
san-induced peritonitis was significantly inhibited in 
Table 1. Acute toxicity in mice
Tetranor-DHLA
LD50 ip in mice
BMTBA
LD50 ip in mice
75.4 mg/kg bw 
(67.35 – 84.42)
588.57 mg/kg bw
(469.22 – 738.27)
LD50 – lethal dose, 50 percent kill
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Carrageenan-induced paw edema in mice 
The influence of the studied compounds in the paw ede-
ma model was examined at three doses of BMTBA (30, 50 
and 100 mg/kg bw) and at two doses of tetranor-DHLA 
(30, 50 mg/kg bw). Indomethacin at a dose of 20 mg/kg 
bw was used as a reference compound (IND20 group). 
The mouse paw became edematous after the injection 
of carrageenan, and edema reached a peak at 3 h in the 
control group (increase by 86.71% of the initial volume). 
The obtained results indicated that the increase in paw 
edema was significantly inhibited in the groups receiving 
BMTBA (BMTBA50 and BTMBA100 groups) or tetranor-
DHLA (tetranor-DHLA30 and tetranor-DHLA50 groups) 
compared to the control group, which was given carra-
geenan alone (Fig. 4; Table 4). 
dIscussIon
This work showed that administration of both tetranor-
DHLA and BMTBA significant ameliorated the inflamma-
tory response in the zymosan-induced peritonitis and 
in the carrageenan-induced hind paw edema models in 
mice. It is noteworthy that the anti-inflammatory ac-
tion of the compounds under study was dose-dependent.
Our results indicated that tetranor-DHLA at a dose of 50 
mg/kg bw significantly reduced hind paw edema, when 
Table 2. Percent inhibition of vascular permeability in zymosan-induced 
peritonitis in mice
Compounds % inhibition
IND10 60.53
tetranor-DHLA10 11.75
tetranor-DHLA30 28.95
tetranor-DHLA50 8.99
BMTBA10 34.64
BMTBA30 31
BMTBA50 31.01
BMTBA100 0
IND10 – indomethacin 10 mg/kg bw; tetranor-DHLA10 – tetranor-DHLA 10 mg/kg 
bw; tetranor-DHLA30 – tetranor-DHLA 30 mg/kg bw; tetranor-DHLA50 – tetranor-
DHLA 50 mg/kg bw; BMTBA 10 – BMTBA 10 mg/kg bw; BMTBA 30 – BMTBA 30 mg/
kg bw; BMTBA 50 – BMTBA 50 mg/kg bw; BMTBA 100 – BMTBA 100 mg/kg bw
Fig. 2.  Vascular permeability changes during zymosan-induced peritonitis in mice.
Data are presented as the mean ± SEM, percentage of control absorbance 
in zymosan-induced peritonitis group, n = 8. Student’s t-test, differences 
significant vs. control group – zymosan-induced peritonitis: * p <0.05;  
** p < 0.02; *** p < 0.01. Groups: IND10 – indomethacin 10 mg/kg bw; 
tetranor-DHLA10 – tetranor-DHLA 10 mg/kg bw; tetranor-DHLA30 – 
tetranor-DHLA 30 mg/kg bw; tetranor-DHLA50 – tetranor-DHLA 50 mg/kg 
bw; BMTBA 10 – BMTBA 10 mg/kg bw; BMTBA 30 – BMTBA 30 mg/kg bw; 
BMTBA 50 – BMTBA 50 mg/kg bw; BMTBA 100 – BMTBA 100 mg/kg bw
Table 3. Percent inhibition of neutrophil infiltration in zymosan-induced 
peritonitis in mice
Compounds % inhibition
Tetranor-DHLA50 80.65
BMTBA50 75.04
tetranor-DHLA50 – tetranor-DHLA 50 mg/kg bw; ip.
BMTBA50 – BMTBA 50 mg/kg bw; ip.
Fig. 3.  Changes in neutrophil infiltration during zymosan-induced peritonitis in 
mice. Data are presented as the mean ± SEM of neutrophil count, n = 8. 
Student’s t-test, differences significant vs. control group – zymosan-induced 
peritonitis: ** p < 0.02; *** p < 0.01. Groups: tetranor-DHLA50 – tetranor-
DHLA 50 mg/kg bw; BMTBA 50 – BMTBA 50 mg/kg bw; ZYM – zymosan
the group receiving BMTBA (BMTBA50 group) and in 
the group treated with tetranor-DHLA (tetranor-DHLA50 
group) compared to the control group, which was given 
zymosan alone (ZYM group) (Fig. 3, Table 3).
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its anti-inflammatory effect after 1 h, 2 h and 3 h was 
compared to the reference non-steroidal anti-inflam-
matory drug (NSAID) indomethacin. The obtained data 
also demonstrated that administration of tetranor-DHLA 
at the same dose (50 mg/kg bw) significantly inhibited 
infiltration of neutrophils. It is surprising that tetranor-
DHLA at the same dose (50 mg/kg bw) did not reduce 
vascular permeability in the zymosan-induced perito-
nitis in mice but its lower dose of 30 mg/kg bw was ef-
ficient in that test.
The LD50 value in mice for tetranor-DHLA was 75.4 mg/kg 
bw; thus the doses used in our experiments were below 
the LD50 for this compound.
BMTBA was the second LA metabolite examined in this 
study. The anti-inflammatory effect of BMTBA at the dose 
of 100 mg/kg bw was evidenced by a significant reduc-
tion of hind paw edema in the BMTBA-treated group. The 
paw edema 1 h after BMTBA treatment was comparable 
to that after the reference NSAID indomethacin, whereas 
after 2 and 3 h BMTBA was even more efficient than in-
domethacin in paw edema reduction.
Surprisingly, BMTBA at the same dose (100 mg/kg bw) 
did not reduce vascular permeability in the zymosan-
induced peritonitis model in mice. BMTBA effects at the 
dose of 30 mg/kg bw were also ambiguous. Namely, while 
the early vascular permeability measured at 30 min of 
Fig. 4.  Effects of pre-treatment with intraperitoneal (a) tetranor-DHLA or (b) BMTBA on paw edema induced by 1% carrageenan (0.05 ml/paw) in mice. The figures show 
percent change in paw volume in relation to the initial volume (before carrageenan injection). Data are expressed as the mean ± SEM of 8 animals per group. Student’s 
t-test, differences significant vs. control group – carrageenan group – * p < 0.05, ** p < 0.02, **** p < 0.001. IND 20 – indomethacin 20 mg/kg bw; tetranor-DHLA30 – 
tetranor-DHLA 30 mg/kg bw; tetranor-DHLA50 – tetranor-DHLA50 mg/kg bw; BMTBA30 – BMTBA 30 mg/kg bw; BMTBA50 – BMTBA 50 mg/kg bw; BMTBA100 – BMTBA 
100 mg/kg bw
Table 4. Percent inhibition of carrageenan-induced paw edema
Compounds % inhibition after 1 h % inhibition after 2 h % inhibition after 3 h
IND20 40.27 25.16 29.5
tetranor-DHLA30 10.51 11.87 14.9
tetranor-DHLA50 38.2 26.1 30.04
BMTBA30 -2.78 -10.05 -12.96
BMTBA50 38.71 27.35 26.49
BMTBA100 35.42 38.13 42.34
IND 20 – indomethacin 20 mg/kg bw., ip.; tetranor-DHLA30 – tetranor-DHLA 30 mg/kg bw., ip; tetranor-DHLA50 – tetranor-DHLA50 mg/kg bw., ip.; BMTBA30 – BMTBA 30 
mg/kg bw., ip.; BMTBA50 – BMTBA 50 mg/kg bw., ip.; BMTBA100 – BMTBA 100 mg/kg bw., ip.
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zymosan-induced peritonitis was significantly reduced 
in the BMTBA30 group, BMTBA at the same dose acted 
as an edemagenic agent, like carrageenan.
On the other hand, BMTBA at the dose of 50 mg/kg bw 
significantly reduced both the early vascular permeability 
and paw edema formation. For this reason, to test the in-
hibition of neutrophil infiltration in zymosan peritonitis 
in mice, we chose the BMTBA50 group. 
The obtained data indicated that administration of BM-
TBA at the dose of 50 mg/kg bw resulted in significant 
inhibition of infiltration of neutrophils. The BMTBA LD50 
value in mice reached 400 mg/kg bw; therefore, the dose 
of 50 mg/kg bw was approximately one tenth of its LD50. 
Thus, based on the obtained results, it appears that BM-
TBA is a potential candidate for a safe and efficacious 
medication in inflammatory diseases.
This study is the first to show the anti-inflammatory ef-
fects of both tetranor-DHLA and BMTBA. However, the 
mechanism of their action is unknown. Both compounds 
under study appear to be efficient antioxidants, like DHLA 
and LA. It is well known that oxidation and inflammation 
are closely interrelated in biological systems [4,12]. Al-
though so far there are no experimental literature data 
on biological activity of LA biotransformation products, 
antioxidant properties of bisnorlipoic acid and tetranor-
lipoic acid and their reduced forms bisnor-DHLA and tet-
ranor-DHLA were confirmed by theoretical studies using 
quantum-chemical computations [24].
In our opinion, the pharmacological effects of tetranor-
DHLA are also associated with the formation of hydrogen 
sulfide (H2S), a novel endogenous, gaseous mediator. Za-
nardo et al. reported that H2S reduced leukocyte infiltra-
tion and edema formation, using the air pouch paradigm 
and the carrageenan-induced hind paw edema model in 
rats [33]. Xu et al. indicated that H2S protected MC3T3-E1 
osteoblastic cells against hydrogen peroxide (H2O2)-in-
duced oxidative injury [30]. Several authors revealed that 
H2S was able to act as an inhibitor of phosphodiesterases 
(PDE), thereby elevating cyclic AMP and/or cyclic GMP 
levels, which could contribute to its anti-inflammatory 
effects [27]. H2S was also shown to reduce expression of 
many pro-inflammatory cytokines and chemokines [5,6].
Already in the 1960s Villarejo and Westley indicated that 
rhodanese (thiosulfate/cyanide sulfurtransferase, TST, EC 
2.8.1.1) catalyzed the reduction of thiosulfate to sulfate 
and H2S when DHLA (or dihydrolipoamide) was used as 
a reducing agent [26]. In 2011 Mikami et al. demonstrat-
ed that H2S was also produced by 3-mercaptopyruvate 
sulfurtransferase (3-mercaptopyruvate/cyanide sulfur-
transferase, MST, EC 2.8.1.2) from 3-mercaptopyruvate, 
when, as in the case of TST, DHLA was used as a reduc-
ing agent [16].
Considering the structural similarity of DHLA and tetra-
nor-DHLA, it can be expected that tetranor-DHLA, as a 
reducing agent, participates in H2S formation catalyzed 
by TST and MST.
As for BMTBA, this compound can act as an antioxidant 
since it is known that S-alk(en)-yl derivatives of thiol com-
pounds (compounds S-substituted by alk(en)yl groups) 
exhibit antioxidant and anti-inflammatory properties.
Yin et al. reported that S-methyl cysteine (SMC) and S-
ethyl cysteine (SEC) intake significantly decreased mal-
onyldialdehyde (MDA) level and increased glutathione 
(GSH) content in the kidney of diabetic mice [32]. Hsu et 
al. in a study in mice found that SEC and SMC, as well as S-
propyl cysteine (SPC), S-allyl cysteine (SAC) and N-acetyl 
cysteine (NAC), provided a marked antioxidant protection 
of enzymes [8]. In the light of structural similarities of 
BMTBA and SMC, the hypothesis assuming antioxidant 
properties of BMTBA seems justified. 
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